Purple Biotech (PPBT) — Cash Flow-to-Debt Ratio
Purple Biotech (PPBT) has a Cash Flow-to-Debt Ratio of -0.13x as of December 2025, meaning its operating cash flow of $-1.04 Million could theoretically repay 0% of its total liabilities ($7.91 Million) in one year. Explore Purple Biotech (PPBT) long-term investment share to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Purple Biotech Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Purple Biotech across 13 annual periods. Also explore Purple Biotech balance sheet assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Purple Biotech (2013–2025)
Year-by-year debt coverage analysis for Purple Biotech. For market capitalisation and broader financial context, see Purple Biotech market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.70x | $-5.54 Million | $7.91 Million | ▲ +79.9% |
| 2024 | -3.48x | $-14.37 Million | $4.13 Million | ▼ -74.8% |
| 2023 | -1.99x | $-19.93 Million | $10.01 Million | ▲ +10.5% |
| 2022 | -2.22x | $-16.73 Million | $7.52 Million | ▲ +24.9% |
| 2021 | -2.96x | $-15.07 Million | $5.09 Million | ▲ +0.8% |
| 2020 | -2.98x | $-12.09 Million | $4.05 Million | ▼ -106.3% |
| 2019 | -1.45x | $-5.58 Million | $3.86 Million | ▲ +36.5% |
| 2018 | -2.28x | $-8.48 Million | $3.72 Million | ▼ -47.7% |
| 2017 | -1.54x | $-8.63 Million | $5.59 Million | ▲ +62.3% |
| 2016 | -4.10x | $-6.26 Million | $1.53 Million | ▼ -71.2% |
| 2015 | -2.39x | $-3.31 Million | $1.38 Million | ▲ +47.9% |
| 2014 | -4.59x | $-4.53 Million | $986.00K | ▼ -1026.9% |
| 2013 | -0.41x | $-512.00K | $1.26 Million | — |